Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity ...

A study shows a 25.6 per cent decline in weight-loss surgeries as more Americans turn to GLP-1 medications like Wegovy and ...

Taking a GLP-1 receptor agonist was associated with a lower risk for cirrhosis and related complications in patients with ...

When food enters the digestive system, specialized cells in the small intestine release GLP-1, initiating a cascade of ...

Recent updates from the American Stroke Association reveal groundbreaking strategies for preventing strokes, which affect ...

Renowned plant-based physician Dr. Michael Greger has released a new book on the risks, benefits, and alternatives to Ozempic ...

Researchers from Mass General Brigham and collaborators found that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 while rates of surgery dropped by one quarter.

New stroke prevention guidelines highlight key interventions for cardiovascular health, as well as emerging evidence on ...

Study of those who started taking blockbuster weight loss drugs in 2021 suggests patients need support services, not just the ...

For patients with opioid use disorder (OUD) and alcohol use disorder (AUD), prescriptions of glucose-dependent insulinotropic ...

After insurance for New York City employees began covering GLP-1 weight-loss injectables, more than 1,000 city workers and ...

In a world increasingly focused on health and wellness, finding effective solutions for weight management can be challenging.